Compare BridgeBio Pharma Inc (BBIO) vs First Solar, Inc. (FSLR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs First Solar, Inc. — how do they compare? BridgeBio Pharma Inc trades at $84.99 (market cap $16.36B), while First Solar, Inc. trades at $227.2 (market cap $25.89B). The key difference: First Solar, Inc. is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals.
| BBIO | FSLR | |
|---|---|---|
Market Cap | $16.36B | $25.89B |
Sector | Health | Technology |
52-Week High | $90.17 | $318.30 |
52-Week Low | $47.29 | $180.05 |
Enterprise Value | $18.14B | $24.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.64, down 1.22% on the day, with a bullish technical signal from moving averages and strong analyst support. Revenue surged to $502.08M in 2025, though net losses widened to -$724.93M, reflecting high R&D spending. Recent news highlights Q2 2026 earnings misses but revenue beats, driven by Attruby sales growth and three late-stage regulatory submissions expected by mid-2027.
Outlook remains optimistic with an 88% buy rating and $104.56 price target, but risks include persistent cash burn, high debt of $1.72B, and negative equity. Key catalysts are FDA decisions in 2027, with success potentially driving significant upside, though failure could exacerbate financial strain.
First Solar (FSLR) trades at $228.27, down 4.62% on the day, amid mixed signals. The stock shows a bullish technical trend with strong moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported robust revenue growth to $5.22B in 2025, with a net income margin of 29.27%, while recent earnings beat expectations in Q1 and Q2 2026. However, multiple class-action lawsuits filed in August 2026 create near-term legal overhang.
The outlook remains positive given analyst consensus favoring a buy rating with a $282.07 price target, implying significant upside. Key risks include legal proceedings and competitive pressures in the solar sector. Earnings growth and operational cash flow strength support long-term value, but investors should weigh legal uncertainties against fundamental strengths.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →
